MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
MYRIAD GENETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$4.21+0.23 (+5.78%)
Close on Oct 19, 2026
- Market cap
- $399.11M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Myriad Genetics has not reported a dividend
No dividend per share appears in Myriad Genetics's annual filings since fiscal 2009.